Next 10 |
home / stock / pacb / pacb articles
Accelerate Diagnostics (NASDAQ: AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. Thi...
Shares of Perficient, Inc (NASDAQ:PRFT) shares rose sharply during Monday's session after the company disclosed an acquisition deal and first-...
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday...
Over the past twenty days of trading, Pacific Biosciences of California Inc. (NASDAQ: PACB), from March 19, 2024 to April 16, 2024 there is a pote...
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The compan...
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.02% to 37,741.96 while...
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial res...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0.13% to 37,784.21 whi...
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the ...
News, Short Squeeze, Breakout and More Instantly...
Pacific Biosciences of California Inc. Company Name:
PACB Stock Symbol:
NASDAQ Market:
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases PR Newswire Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ...
2024-05-13 14:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for PACB on May 13, 2024 12:08PM ET. The previous analyst recommendation was Equal-Weight. PACB was trading at $1.975 at issue of the analyst recommendation. The overall analyst consensus : ...
2024-05-13 14:00:03 ET Tejas Savant from Morgan Stanley issued a price target of $4.00 for PACB on 2024-05-13 12:08:00. The adjusted price target was set to $4.00. At the time of the announcement, PACB was trading at $1.975. The overall price target consensus is at $2.50...